159 related articles for article (PubMed ID: 34620508)
1. Risk stratification and adjuvant chemotherapy after radical resection based on the clinical risk scores of patients with stage IB-IIA non-small cell lung cancer.
Zhai W; Duan F; Li D; Yan Q; Dai S; Zhang B; Wang J
Eur J Surg Oncol; 2022 Apr; 48(4):752-760. PubMed ID: 34620508
[TBL] [Abstract][Full Text] [Related]
2. Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non-small cell lung cancer.
Zhang P; Duan J; Bai H; Wang Z; Gao S; Tan F; Gao Y; Wang X; Wan R; Xu J; He X; Feng X; Yu R; Sun J; Zhao Z; Fei K; Li N; He J; Wang J
Thorac Cancer; 2021 Jan; 12(1):30-39. PubMed ID: 33111432
[TBL] [Abstract][Full Text] [Related]
3. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
4. Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients.
Li X; Zhang C; Sun Z; Yang F; Xiao R; Sui X; Jiang G; Zhong W; Wang J
Lung Cancer; 2019 Jul; 133():75-82. PubMed ID: 31200832
[TBL] [Abstract][Full Text] [Related]
5. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
Yang H; Wang K; Li S; Li Y; Yuan L
Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
[No Abstract] [Full Text] [Related]
6. Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Wen M; Wang L; Wang X; Yang S; Sun Y; Xia J; Zhang Y; Zhang Z; Huang L; Jiang T
Oncol Res Treat; 2020; 43(12):686-693. PubMed ID: 33197924
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
[TBL] [Abstract][Full Text] [Related]
8. Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification.
Isaka T; Ito H; Nakayama H; Yokose T; Yamada K; Masuda M
Lung Cancer; 2020 Jul; 145():111-118. PubMed ID: 32428800
[TBL] [Abstract][Full Text] [Related]
9. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.
Woodard GA; Kratz JR; Haro G; Gubens MA; Blakely CM; Jones KD; Mann MJ; Jablons DM
Clin Lung Cancer; 2021 Nov; 22(6):587-595. PubMed ID: 34544620
[TBL] [Abstract][Full Text] [Related]
10. Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.
Zhai X; Yang L; Chen S; Zheng Q; Wang Z
Cancer Med; 2016 Sep; 5(9):2286-93. PubMed ID: 27367482
[TBL] [Abstract][Full Text] [Related]
11. Influence of adjuvant chemotherapy on survival for patients with completely resected high-risk stage IB NSCLC.
Shen ZQ; Feng KP; Fang ZY; Xia T; Pan S; Ding C; Xu C; Ju S; Chen J; Li C; Zhao J
J Cardiothorac Surg; 2024 Jan; 19(1):1. PubMed ID: 38166960
[TBL] [Abstract][Full Text] [Related]
12. Who are the real high-risk patients with pathological T2N0M0 non-small-cell lung cancer that can benefit from adjuvant chemotherapy?
Hou X; Yang MZ; Li JB; Tan ZH; Long H; Fu JH; Zhang LJ; Lin P; Yang HX
ESMO Open; 2022 Jun; 7(3):100508. PubMed ID: 35688064
[TBL] [Abstract][Full Text] [Related]
13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.
Tsao MS; Sakurada A; Ding K; Aviel-Ronen S; Ludkovski O; Liu N; Le Maître A; Gandara D; Johnson DH; Rigas JR; Seymour L; Shepherd FA
J Thorac Oncol; 2011 Jan; 6(1):139-47. PubMed ID: 21107284
[TBL] [Abstract][Full Text] [Related]
15. Ground Glass Opacity and Adjuvant Chemotherapy in Pathological Stage IB-IIA Lung Adenocarcinoma.
Zhai W; Gong L; Zheng Y; Yan Q; Lai R; Liang D; Wong W; Dai S; Wang J
Front Oncol; 2022; 12():851276. PubMed ID: 35402251
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
Raphael J; Vincent M; Boldt G; Shah PS; Rodrigues G; Blanchette P
Am J Clin Oncol; 2019 May; 42(5):440-445. PubMed ID: 30913091
[TBL] [Abstract][Full Text] [Related]
19. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Pennell NA; Neal JW; Chaft JE; Azzoli CG; Jänne PA; Govindan R; Evans TL; Costa DB; Wakelee HA; Heist RS; Shapiro MA; Muzikansky A; Murthy S; Lanuti M; Rusch VW; Kris MG; Sequist LV
J Clin Oncol; 2019 Jan; 37(2):97-104. PubMed ID: 30444685
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Wei YC; Liu YY; Chen C; Cheng Y; Yin R; Yang F; Ren SX; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yang JJ; Yan HH; Yang XN; Liu SY; Zhou Q; Wu YL
J Clin Oncol; 2021 Mar; 39(7):713-722. PubMed ID: 33332190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]